Meeting Banner
Abstract #1159

Tracking the evolution of individual prostate cancer metastases in patients under the selective pressure of Radium-223 treatment using whole-body radiomics.

Matthew D Blackledge1,2, Dow Mu Koh1,2, David J Collins1,2, Matthew R Orton1,2, Erica Scurr2, Julie Hughes2, Chris Parker1,3, Martin O Leach1,2, and Nina Tunariu1,2

1Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom, 2MRI Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom, 3Urology Department, The Royal Marsden NHS Foundation Trust, London, United Kingdom

Whole-Body Diffusion-Weighted-MRI is emerging as an imaging response biomarker in metastatic bone disease. Tumour heterogeneity resulting in differential response to therapy is a well-recognized phenomenon. We propose that calculating radiomic features from the apparent diffusion coefficients within individual lesions can identify differential response patterns in whole-body bone disease. Robust statistical assessment of radiomic features based on repeatability assessment aids identification of significant changes.

This abstract and the presentation materials are available to members only; a login is required.

Join Here